Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment

07/16/2014 | 08:45pm US/Eastern

By a News Reporter-Staff News Editor at Cancer Weekly -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced it has entered into an agreement with Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays. In alignment with Merck KGaA's strategic approach in personalized medicine, the aim is to develop a patient stratifying diagnostic test that can be used in multiple cancer indications. Merck KGaA, which is actively investing in innovation in the CDx field through a number of partnerships, will leverage Ventana's global leadership position in cancer diagnostics and vast expertise in CDx to achieve new levels of diagnostic clarity for the investigated target. As part of the agreement, Ventana will develop and validate the CDx and ensure its readiness, availability, and adherence to FDA and other health authority standards for future clinical trials (see also Ventana Medical Systems, Inc.).

"Tailoring therapies based on a patient's specific genes, proteins or tissue environment is a key expansion area for oncology. We are very pleased to partner with Merck in Darmstadt, Germany to co-develop a CDx that will play a vital role in improving the quality of care for cancer patients," said Doug Ward, Vice President, Companion Diagnostics, Ventana Medical Systems, Inc. "Ventana is committed to continuing to provide the industry's gold standard in biomarker detection using our proprietary assays as the basis for novel companion diagnostic tests."

This pharma partnership is one of several currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tests that help identify those patients who are most likely to benefit from specific treatments. In addition to the biopharmaceutical division of Merck KGaA, Ventana has announced partnerships with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more. Since 2002, the company has worked with more than 45 biopharmaceutical partners and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally.

Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.

Keywords for this news article include: Cancer, Genetics, Oncology, Ventana Medical Systems Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

(c) 2014 NewsRx LLC

React to this article
Latest news
Date Title
05:22p BAYERISCHE MOTOREN WERKE : 'This is huge for us' ; Reporting local life since 1873
05:22p Big North Announces Private Placement to Existing Shareholders and Other Investors
05:22p JPX GLOBAL : Changes in Registrant's Certifying Accountant (form 8-K)
05:22p QNB Corp. Reports Fourth Quarter Earnings
05:22pDJBROADCOM : Profit Soars on Sales Growth, Lower Costs
05:22p Fitch Upgrades 3 Classes of JPMCCM 2005-LDP1
05:21p J SAINSBURY : Duty chemists
05:21p DELTA AIR LINES : flight lands in Vegas with pilot locked out of cockpit
05:21p ALNYLAM PHARMACEUTICALS : Thursday 1/29 Insider Buying Report: ALNY, SSB
05:21p TUESDAY MORNING : posts 2Q profit
Latest news
Advertisement
Hot News 
GROUPE STERIA : Sopra Steria Group: Financial calendar 2015
NEXT FIFTEEN COMMUNICATIONS : Raises GBP4.3 Million, To Beat Expectations (ALLISS)
PERFORMANT FINANCIAL : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
VENAXIS : Other Events, Financial Statements and Exhibits (form 8-K)
GEVO : Announces Pricing of Public Offering of Common Stock and Warrants
Most Read News
03:30a UK MORNING BRIEFING : Royal Dutch Shell Leads London Losses
01/28 SCHRODERS : raises fees on £1bn Corporate Bond fund
01/28 CANACOL ENERGY : Tests 21 MMSCFPD at Clarinete 1 Gas Discovery in Colombia
01/28 SAMSUNG ELECTRONICS : Qualcomm says key customer passed on new chip, stock drops
01/28 Qualcomm says key customer passed on new chip, stock drops
Most recommended articles
05:18pDJTE Connectivity Files 8K - Regulation FD
05:18pDJNewcrest Raises Annual Copper, Gold Output Goal
05:14p Broadcom's fourth-quarter results exceed expectations
05:13p Google fourth-quarter revenue misses Wall Street target
05:07p Amazon sales rise in holiday quarter, shares jump
Dynamic quotes  
ON
| OFF